Basic and clinical studies on BMY-28100 in urology

Yoshitsugu Nasu, Daisuke Yamada, Masaya Tsugawa, Mikio Kishi, Hiromi Kumon, Hiroyuki Ohmori, Katsuichi Nanba, Nobuyuki Akazawa, Akihiro Mizuno

Research output: Contribution to journalArticlepeer-review


We performed basic and clinical studies on BMY-28100, a new orally active antimicrobial agent, in urology. 1) BMY-28100 had a broad spectrum, showing strong antibacterial activity against Gram-positive bacteria, includingStaphylococcus aureus, Staphylococcus epidermidis and Gram-negative bacteria, including Escherichia coli, Klebsiella pneumoniaeand Proteus mirabilis 2) Two patients with acute uncomplicated cystitis showed excellent or good response to BMY-28100 treatment. Six of 14 patients with complicated urinary tract infection showed excellent or moderateresponse. 3) No side effects were observed. Abnormal laboratory findings were noted in 5 episodes in 3 patients, but were mild and transient.

Original languageEnglish
Pages (from-to)606-618
Number of pages13
Publication statusPublished - Jan 1 1989

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Infectious Diseases
  • Pharmacology
  • Drug Discovery
  • Oncology


Dive into the research topics of 'Basic and clinical studies on BMY-28100 in urology'. Together they form a unique fingerprint.

Cite this